[Molecular factors determine primary and secondary therapy of breast carcinoma].
The clinical oncology realizes that the classical approach with systemic adjuvant chemo- and hormonal therapies is not sufficient and will be challenged by cellular and molecular structures which reflect the targets for new therapeutic approaches. These targets are key proteins involved in the signal transduction cascade. In human tumors these proteins have either lost their biological functionality by oncogenic mutations or are constitutively activated. The molecular classification of primary breast cancer was performed by assessing the following factors: estrogen- and progesterone receptors, ERbB-2 mutated p53, uPA, PAI-I, VEGF, DNA-Index and S-Phase. These factors are of prognostic and predictive value.
Eppenberger
U
U
Stiftung Tumorbank Basel, Universitäts-Frauenklinik.
Kueng
W
W
Eppenberger-Castori
S
S
von Landenberg
E M
EM
Müller
H
H
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor